Rosen Law Firm Urges agilon Health Investors to Seek Counsel Before Important Deadline in Securities Class Action

New York, New York, January 18, 2026 — Rosen Law Firm, one of the world’s most respected securities litigation firms, has issued a comprehensive notice to investors of agilon health, inc. (NYSE: AGL) regarding a federal securities class action lawsuit. The firm is reminding all qualifying shareholders of a critical deadline — March 2, 2026 — by which they must take action if they wish to serve as lead plaintiff or participate in potential recovery efforts in the case first filed by Rosen.

The class action concerns alleged violations of federal securities laws during a period between February 26, 2025 and August 4, 2025 (the “Class Period”), during which time Rosen asserts that agilon health made materially misleading statements and failed to disclose critical business information that negatively impacted investors when the true facts became known to the market.

This advisory is part of ongoing efforts by Rosen Law Firm to ensure that investors are informed about their legal rights and options, and to encourage them to secure qualified counsel ahead of the upcoming deadline.

What the Class Action Is About

According to the complaint, defendants allegedly issued forecasts and disclosures about agilon health’s business prospects and financial condition that were materially false or misleading. Specifically, Rosen claims that:

• Defendants allegedly provided revenue and performance guidance they knew, or should have known, was not realistic given industry challenges and business conditions.
• The company purportedly overstated the financial benefit of so-called “strategic actions” to mitigate risk.
• Key operational and financial information was allegedly withheld or misrepresented, causing agilon’s stock price to be artificially inflated during the Class Period.

When the truth about these matters became widely known, stockholders allegedly suffered financial losses. This forms the basis of the allegations in the securities class action lawsuit filed by Rosen.

Legal Context and Investor Harm

Securities class actions typically arise when publicly traded companies are accused of violating federal securities laws — especially when it is alleged that they made false or misleading statements that investors relied on when purchasing company shares. If the allegations are proven, investors may be entitled to monetary compensation for damages suffered in the market.

In this case, Rosen Law Firm alleges that agilon health’s public statements and disclosures about its financial outlook and business operations did not accurately reflect the company’s true condition. As a result, the firm believes that investors who purchased agilon stock during the Class Period were harmed when the company’s stock price fell as the truth entered the market.

Important Deadlines and Legal Options

A key component of this notice is the reminder about the deadline of March 2, 2026. Rosen Law Firm is advising investors who wish to seek appointment as lead plaintiff in the lawsuit to file a motion with the court no later than that date.

The lead plaintiff plays a central role in class action litigation, serving as the primary representative for all class members and having authority to direct aspects of the case. Selecting the proper lead plaintiff can be crucial, as it often affects litigation strategy and potential outcomes.

Investors who do not wish to serve as lead plaintiff may still remain in the class and benefit from a possible settlement or judgment. However, they must be aware of the timeline for moving forward and the legal steps involved.

Why Investors Should Consider Qualified Counsel

Rosen Law Firm emphasizes the importance of choosing experienced legal representation for securities class actions. The press release notes that many firms that send investor notices may not actually litigate securities cases directly, but rather refer clients to other firms or lack experience in leading complex lawsuits.

In contrast, Rosen Law Firm highlights its own background, including significant past settlements and recognitions in securities litigation:

• Rosen has secured one of the largest class action settlements involving a Chinese company in U.S. history.
• The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017, and has remained in the top four since 2013.
• Rosen achieved over $438 million in investor recoveries in 2019 alone.
• Founding partner Laurence Rosen has been recognized as a “Titan of the Plaintiffs’ Bar” by Law360.

The firm’s attorneys have also received accolades from legal ranking organizations such as Lawdragon and Super Lawyers, reinforcing their credentials in this area of law.

How Investors Can Take Action

Investors interested in joining the class action or seeking to become lead plaintiff have several options:

• Submit a form online: Investors can complete the class action form via the Rosen Law Firm website to participate in the case.
• Contact counsel directly: Interested investors may call the firm’s toll-free line or send an email to request more information about the lawsuit.
• Seek qualified legal representation: Investors may also retain private counsel of their choice, though acting before the deadline is crucial.

The press release includes specific contact details, including a toll-free number and email address for inquiries, so that investors can gather further information about the class action process.

Class Certification and Representation

It is important to note that, as of the date of the press release, no class has been certified in this action. Until a court certifies the class, investors are not legally represented by counsel unless they hire one. This is a standard procedural point in securities litigation that investors should understand before proceeding.

Once the court certifies a class, all qualifying investors who have not opted out will be bound by the outcome of the litigation, whether it results in a settlement, trial verdict, or dismissal.

Background on agilon Health and Shareholder Concerns

agilon health, inc. is a healthcare company focused on transforming the way care is delivered and paid for, particularly in the Medicare Advantage space. While this press release does not go into detail about the company’s business model, it echoes concerns raised more broadly in other legal notices about investor losses tied to alleged misrepresentations.

Other law firms have also issued investor alerts and notices in relation to agilon health, indicating that multiple securities law practices are engaged in similar litigation efforts on behalf of shareholders. These separate notices have reinforced the seriousness of the allegations and the potential for investor recovery.

Legal and Market Impact

Class action lawsuits like this one have several potential implications for companies and the broader market. Securities class actions can:

• Lead to substantial financial settlements or judgments against defendants.
• Affect a company’s public perception and relationship with investors.
• Encourage corporate transparency and stronger compliance with disclosure laws.

For investors, participating in a class action represents a way to seek redress for economic losses that may have resulted from alleged corporate misconduct or misrepresentation. However, legal processes can be lengthy, and outcomes are never guaranteed.

Summary

In summary, Rosen Law Firm’s press release serves as a comprehensive call to action for investors who purchased agilon health securities between February 26, 2025 and August 4, 2025. The notice focuses on the upcoming March 2, 2026 lead plaintiff deadline, encourages investors to secure experienced legal counsel, and outlines the process for joining or participating in the ongoing securities class action.

As this legal matter continues to develop, investors with qualifying losses have an opportunity to pursue potential compensation — provided they act before the deadline and understand their legal rights and options in this complex area of law.